POLE-mutated and MSI endometrial cancers are associated with high neo-antigen loads and abundant TILs, accompanied by overexpression of PD-1/PD-L1, making them ideal candidates for PD-1 targeted immunotherapy. The gene discussed is POLE; the disease is endometrial cancer.